Beyond complete endoscopic healing: Goblet appearance using an endocytoscope to predict future sustained clinical remission in ulcerative colitis

被引:14
作者
Takishima, Kazumi [1 ]
Maeda, Yasuharu [1 ]
Ogata, Noriyuki [1 ]
Misawa, Masashi [1 ]
Mori, Yuichi [1 ,4 ]
Homma, Mayumi [2 ]
Nemoto, Tetsuo [2 ]
Miyata, Yuki [1 ]
Akimoto, Yoshika [1 ]
Mochida, Kentaro [1 ]
Takashina, Yuki [1 ]
Tanaka, Kenta [1 ]
Ichimasa, Katsuro [1 ]
Nakamura, Hiroki [1 ]
Sasanuma, Seiko [1 ]
Kudo, Toyoki [1 ]
Hayashi, Takemasa [1 ]
Wakamura, Kunihiko [1 ]
Miyachi, Hideyuki [1 ]
Baba, Toshiyuki [1 ]
Ishida, Fumio [1 ]
Ohtsuka, Kazuo [3 ]
Kudo, Shin-ei [1 ]
机构
[1] Showa Univ, Northern Yokohama Hosp, Digest Dis Ctr, 35-1 Tsuzuki, Yokohama, Kanagawa 2248503, Japan
[2] Showa Univ, Northern Yokohama Hosp, Dept Diagnost Pathol, Yokohama, Kanagawa, Japan
[3] Tokyo Med & Dent Univ, Med Hosp, Dept Endoscopy, Tokyo, Japan
[4] Univ Oslo, Clin Effectiveness Res Grp, Oslo, Norway
关键词
histologic remission; microscopic endoscopy; treat to target; ulcerative colitis; COLORECTAL LESIONS; CHROMOENDOSCOPY SCORE; CLASSIFICATION; RELAPSE; PICASSO; RISK;
D O I
10.1111/den.14202
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives Complete endoscopic healing, defined as Mayo endoscopic score (MES) = 0, is an optimal target in the treatment of ulcerative colitis (UC). However, some patients with MES = 0 show clinical relapse within 12 months. Histologic goblet mucin depletion has emerged as a predictor of clinical relapse in patients with MES = 0. We observed goblet depletion in vivo using an endocytoscope, and analyzed the association between goblet appearance and future prognosis in UC patients. Methods In this retrospective cohort study, all enrolled UC patients had MES = 0 and confirmed clinical remission between October 2016 and March 2020. We classified the patients into two groups according to the goblet appearance status: preserved-goblet and depleted-goblet groups. We followed the patients until March 2021 and evaluated the difference in cumulative clinical relapse rates between the two groups. Results We identified 125 patients with MES = 0 as the study subjects. Five patients were subsequently excluded. Thus, we analyzed the data for 120 patients, of whom 39 were classified as the preserved-goblet group and 81 as the depleted-goblet group. The patients were followed-up for a median of 549 days. During follow-up, the depleted-goblet group had a significantly higher cumulative clinical relapse rate than the preserved-goblet group (19% [15/81] vs. 5% [2/39], respectively; P = 0.02). Conclusions Observing goblet appearance in vivo allowed us to better predict the future prognosis of UC patients with MES = 0. This approach may assist clinicians with onsite decision-making regarding treatment interventions without a biopsy.
引用
收藏
页码:1030 / 1039
页数:10
相关论文
共 27 条
  • [21] Endocytoscopy can be used to assess histological healing in ulcerative colitis
    Nakazato, Yoshihiro
    Naganuma, Makoto
    Sugimoto, Shinya
    Bessho, Rieko
    Arai, Mari
    Kiyohara, Hiroki
    Ono, Keiko
    Nanki, Kosaku
    Mutaguchi, Makoto
    Mizuno, Shinta
    Kobayashi, Taku
    Hosoe, Naoki
    Shimoda, Masayuki
    Abe, Takayuki
    Inoue, Nagamu
    Ogata, Haruhiko
    Iwao, Yasushi
    Kanai, Takanori
    [J]. ENDOSCOPY, 2017, 49 (06) : 560 - 563
  • [22] Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa
    Ozaki, Ryo
    Kobayashi, Taku
    Okabayashi, Shinji
    Nakano, Masaru
    Morinaga, Shojiroh
    Hara, Atsuko
    Ohbu, Makoto
    Matsuoka, Kentaro
    Toyonaga, Takahiko
    Saito, Eiko
    Hisamatsu, Tadakazu
    Hibi, Toshifumi
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 (11) : 1288 - 1294
  • [23] The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
    Satsangi, J.
    Silverberg, M. S.
    Vermeire, S.
    Colombel, J-F
    [J]. GUT, 2006, 55 (06) : 749 - 753
  • [24] COATED ORAL 5-AMINOSALICYLIC ACID THERAPY FOR MILDLY TO MODERATELY ACTIVE ULCERATIVE-COLITIS - A RANDOMIZED STUDY
    SCHROEDER, KW
    TREMAINE, WJ
    ILSTRUP, DM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (26) : 1625 - 1629
  • [25] STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
    Turner, Dan
    Ricciuto, Amanda
    Lewis, Ayanna
    D'Amico, Ferdinando
    Dhaliwal, Jasbir
    Griffiths, Anne M.
    Bettenworth, Dominik
    Sandborn, William J.
    Sands, Bruce E.
    Reinisch, Walter
    Schoelmerich, Juergen
    Bemelman, Willem
    Danese, Silvio
    Mary, Jean Yves
    Rubin, David
    Colombel, Jean-Frederic
    Peyrin-Biroulet, Laurent
    Dotan, Iris
    Abreu, Maria T.
    Dignass, Axel
    [J]. GASTROENTEROLOGY, 2021, 160 (05) : 1570 - 1583
  • [26] A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
    Ungaro, Ryan
    Colombel, Jean-Frederic
    Lissoos, Trevor
    Peyrin-Biroulet, Laurent
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (06) : 874 - 883
  • [27] Miami classification for probe-based confocal laser endomicroscopy
    Wallace, M.
    Lauwers, G. Y.
    Chen, Y.
    Dekker, E.
    Fockens, P.
    Sharma, P.
    Meining, A.
    [J]. ENDOSCOPY, 2011, 43 (10) : 882 - 891